SCHEMBL31227596

SCHEMBL31227596

COC(=O)c1ccc(-c2nc(C)no2)cc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 3/20 0.47
RARB P10826 3/20 0.47
RARG P13631 3/20 0.47
NPC1 O15118 5/20 0.45
RAB9A P51151 4/20 0.45
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 2/20 0.45
CASP3 P42574 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
S1PR1 P21453 1/20 0.45
S1PR3 Q99500 1/20 0.45
MAPT P10636 5/20 0.44
ACHE P22303 1/20 0.43
TP53 P04637 3/20 0.43
ATM Q13315 2/20 0.42
MEN1 O00255 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31227099 0.86 RARB (0.60) RARARARBRARGS1PR1S1PR3
SCHEMBL31227524 0.84 RARA (0.49) RARARARBRARGS1PR1S1PR3
SCHEMBL2774180 0.79 NPC1 (0.52) RARARARBRARGNPC1RAB9A
SCHEMBL2771651 0.79 S1PR1 (0.57) RARARARBRARGNPC1RAB9A
SCHEMBL2774919 0.79 S1PR1 (0.64) RARARARBRARGNPC1RAB9A
SCHEMBL2772143 0.78 S1PR1 (0.58) RARARARBRARGNPC1RAB9A
SCHEMBL1169327 0.77 MAPT (0.64) NPC1RAB9AKMT2AALDH1A1SMN1; SMN2
SCHEMBL1586393 0.77 HCRTR1 (0.51) NPC1RAB9AKMT2AALDH1A1SMN1; SMN2
SCHEMBL2773650 0.77 S1PR1 (0.62) RARARARBRARGNPC1RAB9A
SCHEMBL2774458 0.77 S1PR1 (0.58) RARARARBRARGNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors INITIAL THERAPEUTICS, INC. (US) 2024-12-05 US disclosed
WO-2024226875-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS INITIAL THERAPEUTICS, INC. (US) 2024-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors MYCBP, MYC, MYCBP2 RARA 1399/4885RARB 813/4885RARG 988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.